Meeting
2019 ASCO Annual Meeting
Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).
Authors
Ines Esteves Domingues Pires Da Silva
Melanoma Institute Australia, Sydney, Australia
Ines Esteves Domingues Pires Da Silva , Tasnia Ahmed , Serigne Lo , Rajat Rai , Jessica Louise Smith , John J. Park , Caroline Nabhan , Richard A. Scolyer , Matteo S. Carlino , Jennifer Leigh McQuade , Douglas Buckner Johnson , Georgina V. Long , Alexander M. Menzies
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9542)
DOI
10.1200/JCO.2019.37.15_suppl.9542
Abstract #
9542
Poster Bd #
113
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).
First Author: F. Stephen Hodi
Poster
2020 ASCO Virtual Scientific Program
The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab.
First Author: Vincent The-Luc Ma
Poster
2017 ASCO Annual Meeting
Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM).
First Author: Douglas Buckner Johnson
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
First Author: Caroline Robert